ProNGF AS A NEW BIOMARKER IN THYROID CANCER : OR2
IDENTIFICATION AND SYNERGISTIC TARGETING OF FLT3-ACTIVATED PATHWAYS IN ACUTE MYELOID LEUKAEMIA : OR5
EPHA2 ANTIBODY INCREASES SENSITIVITY OF U87 GLIOBLASTOMA CELLS TO IRRADIATION : OR6
AIMING FOR THE RIGHT QUALITY IMPROVEMENT TARGET: CROSS-SECTIONAL DATA EXPLORING OUTPATIENTS' PRIORITIES AND PREFERENCES FOR QUALITY IMPROVEMENT IN TERTIARY CLINICS : OR7
THE TOBACCO SMOKING PROFILE OF CLIENTS ATTENDING A MEDICALLY SUPERVISED INJECTING CENTRE : OR8
DEVELOPMENT OF ACTION LIMITS FOR PATIENT ERROR DETECTION FOR AN EPID-BASED REAL-TIME DELIVERY VERIFICATION SYSTEM : OR9
ASSESSMENT OF BLOOD TRANSFUSION PRACTICES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE ERA OF HYPOMETHYLATING AGENTS. : OR10
PREDICTORS OF MDT REVIEW AND THE IMPACT ON LUNG CANCER SURVIVAL FOR HNELHD RESIDENTS TREATED IN THE PUBLIC SECTOR : OR11
MONTE-CARLO SIMULATIONS OF THE CLINICAL BENEFITS FROM THERAPEUTIC DRUG MONITORING OF SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS : OR12
PANEL TESTING FOR BREAST CANCER RISK ASSESSMENT: IS IT JUST BECAUSE WE CAN RATHER THAN SHOULD? : OR15
PATIENT PERSPECTIVES ON ISSUES OF ACCESS TO CANCER CARE ACROSS THE CARE CONTINUUM : OR16
DEVELOPMENT OF NOVEL MULTIPLE REACTION MONITORING (MRM) ASSAY FOR BIOMARKER QUANTITATION IN CANCER CELLS : PP1
ASSESSMENT OF EPIDEMIOLOGIC PROFILE OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN HUNTER REGION : PP2
THE EFFECTS OF ALTERED CD9 AND CD151 EXPRESSION ON PROSTATE EXOSOMES : PP4
IS VTE PROPHYLAXIS SAFE IN HAEMATOLOGICAL CANCERS UNDERGOING AUTOLOGOUS TRANSPLANTATION? : PP5
TECHNIQUES FOR IMPROVING EMOTIONAL CONTENT OF ONLINE COMMUNICATIONS – A SYSTEMATIC REVIEW : PP6
ADVANCING COLLABORATIVE QUALITY IMPROVEMENT IN TERTIARY SETTINGS: DO CHRONIC DISEASE OUTPATIENTS AND HEALTH PROFESSIONALS IDENTIFY SIMILAR TYPES AND NUMBERS OF QUALITY INITIATIVES? : PP7
THERAPEUTIC DRUG MONITORING FOR CANCER PATIENTS RECEIVING CHEMOTHERAPY : PP9
EVIDENCE-PRACTICE GAPS FOR AUSTRALIAN GENERAL PRACTITIONERS (GP) IN ASSISTING PREGNANT WOMEN TO QUIT : PP11
INDIGENOUS COUNSELLING AND NICOTINE (ICAN) QUIT IN PREGNANCY – DEVELOPING AN EVIDENCE-BASED INTERVENTION FOR SMOKING CESSATION FOR INDIGENOUS PREGNANT WOMEN : PP12
DEVELOPING A NOVEL MOUSE MODEL OF LUNG CANCER : PP13
PROSTATE CANCER BIOMARKERS: ARE EXTRACELLULAR VESICLES THE SOLUTION? : PP14
A NEW VENTURE FOR THE HUNTER CANCER BIOBANK-ESTABLISHMENT OF SEQUENTIAL BLOOD COLLECTION FOR BRAIN CANCER RESEARCH : PP16
SIFTING DATA FROM THE CLINICAL COALFACE: DATAMINING IN RADIATION ONCOLOGY TO AID CLINICAL DECISIONS : PP17
DETERMINING THE MECHANISM OF LEUKAEMOGENESIS INDUCED BY SHWACHMAN-DIAMOND SYNDROME (SDS) USING COMPARATIVE AND QUANTITATIVE PROTEOMICS : PP18
CHEMICAL PROTEOMICS TO IDENTIFY THE MECHANISM OF PROTEIN PHOSPHATASE 2A (PP2A) INHIBITION IN ACUTE MYELOID LEUKAEMIA (AML) : PP19
A SURVEY OF MEDICAL STUDENTS' UNDERSTANDING AND ATTITUDE TOWARDS MEDICAL ONCOLOGY: A PILOT STUDY : PP21
ROLE OF REDUCED PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, EXPRESSION IN LUMINAL B BREAST CANCER CELL LINE DNA DAMAGE REPAIR PATHWAY : PP22
A CLINICAL PRACTICE CHANGE INTERVENTION TO INCREASE DIETITIAN PROVISION OF DEPRESSION SCREENING AND REFERRAL FOR HEAD AND NECK CANCER PATIENTS : PP23
CONTINUED TOBACCO SMOKING, ALCOHOL USE AND DEPRESSIVE SYMPTOMS IN A SAMPLE OF HEAD AND NECK CANCER PATIENTS ABOUT TO UNDERGO RADIOTHERAPY : PP24
BASAL-LIKE BREAST CANCER SUBGROUPS UNCOVERED BY GENOMIC AND TRANSCRIPTOMIC PROFILES AND OVERALL SURVIVAL OUTCOMES : PP25
EPID DOSIMETRY FOR CREDENTIALING IMRT TREATMENTS OF DIFFERENT CENTRES : PP26
ASSOCIATION OF THE POLYMORPHIC INTRON 3 16 BP DUPLICATION IN TP53 (RS17878362) WITH A LOW Δ40P53:P53 RATIO AND BETTER OUTCOME IN BREAST CANCER : PP27
THE ESSENTIAL ROLE OF ANATOMICAL PATHOLOGISTS IN TISSUE BIOBANKING – A WIN- WIN SITUATION : PP28
REDUCED EXPRESSION OF PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, IN BREAST CANCER DNA DAMAGE REPAIR PATHWAYS : PP29
BAALC CAN CONTROL THE SENSITIVITY OF AML CELLS TO CHEMOTHERAPEUTICS : PP30
A NOVEL COMBINATORIAL OPTIMISATION APPROACH FOR FEATURE SELECTION VIA INTEGRATION OF INFORMATION FROM MULTIPLE DATASETS : PP31
CHARACTERISATION OF A NOVEL PP2A INHIBITORY ONCOPROTEIN IN ACUTE MYELOID LEUKAEMIA (AML) : PP32
THE PROTEIN PHOSPHATASE INHIBITOR CANTHARIDIN, POTENTIATES THE EFFECT OF ALL-TRANS RETINOIC ACID IN ACUTE PROMYLOCYTIC LEUKEMIA CELLS : PP33
ENHANCING THE EFFICACY OF TYROSINE KINASE INHIBITORS THROUGH BIO-POLYMERIC ALBUMIN HYBRID NANOPARTICLES IN BREAST CANCER : PP34
PATHWAYS TO SMOKING CARE IMPLEMENTATION PROJECT: STAGE 2 : PP35
COMPARING DIGITAL VERSUS VISUAL SCORING METHODS FOR IMMUNOHISTOCHEMICAL STAINING: A CASE STUDY IN THE HUNTER CANCER BIOBANK : PP36
HOW INTRINSIC ARE LUMINAL BREAST CANCER SUBTYPES? : PP37
REVISION OF MOLECULAR BREAST CANCER SUBTYPES : PP38
THE EFFECTIVENESS OF THE PUBLIC DIRECT ACCESS COLONOSCOPY SERVICE IMPLEMENTED AT JOHN HUNTER HOSPITAL : PP39
IDENTIFYING THE FUNCTIONAL ROLE OF TSR, A NOVEL DRUG TARGET IN AML : PP40
DEVELOPMENT AND TESTING OF A DECISION AID FOR WOMEN CONSIDERING NEOADJUVANT SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER (STUDY IN PROGRESS) : PP42
THE SEARCH FOR NOVEL TREATMENT AGENTS FOR PANCREATIC CANCER: TALES FROM THE LAND AND SEA : PP44
A BISPIDINONE ANALOGUE INDUCES AN APOPTOSIS-MEDIATED CYTOTOXIC EFFECT ON PANCREATIC CANCER CELLS IN VITRO : PP45